These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 12733711)

  • 41. A novel missense mutation Ile538Val in the fibroblast growth factor receptor 3 in hypochondroplasia. Mutations in brief no. 122. Online.
    Grigelioniené G; Hagenäs L; Eklöf O; Neumeyer L; Haereid PE; Anvret M
    Hum Mutat; 1998; 11(4):333. PubMed ID: 10215410
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mutations of the fibroblast growth factor receptor-3 gene in achondroplasia.
    Rousseau F; Bonaventure J; Legeai-Mallet L; Pelet A; Rozet JM; Maroteaux P; Le Merrer M; Munnich A
    Horm Res; 1996; 45(1-2):108-10. PubMed ID: 8742128
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Achondroplasia: recent advances in diagnosis and treatment.
    Tanaka H
    Acta Paediatr Jpn; 1997 Aug; 39(4):514-20. PubMed ID: 9316303
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Growth hormone therapy in hypochondroplasia.
    Ramaswami U; Hindmarsh PC; Brook CG
    Acta Paediatr Suppl; 1999 Feb; 88(428):116-7. PubMed ID: 10102069
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical and radiographic features of a family with hypochondroplasia owing to a novel Asn540Ser mutation in the fibroblast growth factor receptor 3 gene.
    Mortier G; Nuytinck L; Craen M; Renard JP; Leroy JG; de Paepe A
    J Med Genet; 2000 Mar; 37(3):220-4. PubMed ID: 10777366
    [No Abstract]   [Full Text] [Related]  

  • 46. Clinical and genetic heterogeneity of hypochondroplasia.
    Rousseau F; Bonaventure J; Legeai-Mallet L; Schmidt H; Weissenbach J; Maroteaux P; Munnich A; Le Merrer M
    J Med Genet; 1996 Sep; 33(9):749-52. PubMed ID: 8880574
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Favorable Growth Hormone Treatment Response in a Young Boy with Achondroplasia.
    Krstevska-Konstantinova M; Stamatova A; Gucev Z
    Med Arch; 2016 Apr; 70(2):148-50. PubMed ID: 27147792
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Mutations of FGFR3 gene cause 3 types of nanisms with variably severity: achondroplasia, thanatophoric nanism and hypochondroplasia].
    Rousseau F; Bonaventure J; Le Merrer M; Maroteaux P; Munnich A
    Ann Endocrinol (Paris); 1996; 57(3):153. PubMed ID: 8949408
    [No Abstract]   [Full Text] [Related]  

  • 49. Asn540Lys mutation in fibroblast growth factor receptor 3 and phenotype in hypochondroplasia.
    Grigelioniené G; Eklöf O; Laurencikas E; Ollars B; Hertel NT; Dumanski JP; Hagenäs L
    Acta Paediatr; 2000 Sep; 89(9):1072-6. PubMed ID: 11071087
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [From gene to disease; achondroplasia and other skeletal dysplasias due to an activating mutation in the fibroblast growth factor].
    van Ravenswaaij-Arts CM; Losekoot M
    Ned Tijdschr Geneeskd; 2001 Jun; 145(22):1056-9. PubMed ID: 11414167
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PTH has the potential to rescue disturbed bone growth in achondroplasia.
    Ueda K; Yamanaka Y; Harada D; Yamagami E; Tanaka H; Seino Y
    Bone; 2007 Jul; 41(1):13-8. PubMed ID: 17466614
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Achondroplasia-hypochondroplasia complex in a newborn infant.
    Huggins MJ; Smith JR; Chun K; Ray PN; Shah JK; Whelan DT
    Am J Med Genet; 1999 Jun; 84(5):396-400. PubMed ID: 10360392
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical Manifestations and Outcomes of 20 Korean Hypochondroplasia Patients with the FGFR3 N540K variant.
    Kim HY; Lee YA; Shin CH; Cho TJ; Ko JM
    Exp Clin Endocrinol Diabetes; 2023 Mar; 131(3):123-131. PubMed ID: 36442838
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Yearly stepwise increments of the growth hormone dose results in a better growth response after four years in girls with Turner syndrome. Dutch Working Group on Growth Hormone.
    van Teunenbroek A; de Muinck Keizer-Schrama SM; Stijnen T; Jansen M; Otten BJ; Delemarre-van de Waal HA; Vulsma T; Wit JM; Rouwé CW; Reeser HM; Gosen JJ; Rongen-Westerlaken C; Drop SL
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4013-21. PubMed ID: 8923853
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Updated treatment of achondroplasia].
    Seino Y
    Clin Calcium; 2009 Mar; 19(3):432-6. PubMed ID: 19252254
    [TBL] [Abstract][Full Text] [Related]  

  • 56. GH treatment and its effect on bone mineral density, bone maturation and growth in short children born small for gestational age: 3-year results of a randomized, controlled GH trial.
    Arends NJ; Boonstra VH; Mulder PG; Odink RJ; Stokvis-Brantsma WH; Rongen-Westerlaken C; Mulder JC; Delemarre-Van de Waal H; Reeser HM; Jansen M; Waelkens JJ; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2003 Dec; 59(6):779-87. PubMed ID: 14974922
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term effects of growth hormone (GH) treatment on body composition and bone mineral density in short children born small-for-gestational-age: six-year follow-up of a randomized controlled GH trial.
    Willemsen RH; Arends NJ; Bakker-van Waarde WM; Jansen M; van Mil EG; Mulder J; Odink RJ; Reeser M; Rongen-Westerlaken C; Stokvis-Brantsma WH; Waelkens JJ; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):485-92. PubMed ID: 17561977
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Final height in children with idiopathic growth hormone deficiency treated with a fixed dose of recombinant growth hormone.
    Rachmiel M; Rota V; Atenafu E; Daneman D; Hamilton J
    Horm Res; 2007; 68(5):236-43. PubMed ID: 17396034
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recombinant human growth hormone plus recombinant human insulin-like growth factor-1 coadministration therapy in short children with low insulin-like growth factor-1 and growth hormone sufficiency: results from a randomized, multicenter, open-label, parallel-group, active treatment-controlled trial.
    Backeljauw PF; Miller BS; Dutailly P; Houchard A; Lawson E; Hale DE; Reiner B; Sperling MA;
    Horm Res Paediatr; 2015; 83(4):268-79. PubMed ID: 25765099
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Short Children with CHARGE Syndrome: Do They Benefit from Growth Hormone Therapy?
    Dörr HG; Boguszewski M; Dahlgren J; Dunger D; Geffner ME; Hokken-Koelega AC; Lindberg A; Polak M; Rooman R;
    Horm Res Paediatr; 2015; 84(1):49-53. PubMed ID: 26044035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.